Members |
targetComponentId |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage I |
American Joint Committee on Cancer stage I (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IA |
American Joint Committee on Cancer stage IA (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IB |
American Joint Committee on Cancer stage IB (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IC |
American Joint Committee on Cancer stage IC (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIA |
American Joint Committee on Cancer stage IIA (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIB |
American Joint Committee on Cancer stage IIB (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage III |
American Joint Committee on Cancer stage III (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIA |
American Joint Committee on Cancer stage IIIA (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIB |
American Joint Committee on Cancer stage IIIB (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IIIC |
American Joint Committee on Cancer stage IIIC (qualifier value) |
Epithelial ovarian tumor, International Federation of Gynecology and Obstetrics stage IV |
American Joint Committee on Cancer stage IV (qualifier value) |
Epithelial ovarian tumour, FIGO stage IVA |
American Joint Committee on Cancer stage IVA (qualifier value) |
Epithelial ovarian tumour, FIGO stage IVB |
American Joint Committee on Cancer stage IVB (qualifier value) |
Epithelial stromal corneal dystrophy |
Epithelial basement membrane dystrophy (disorder) |
Epithelial tumor, benign, no International Classification of Diseases for Oncology subtype |
Benign epithelial neoplasm |
Epithelioid hemangioendothelioma |
Epithelioid hemangioendothelioma, malignant (morphologic abnormality) |
Epoetin alfa 10000unt/mL injection |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
Epoetin alfa 10000unt/mL injection solution 1mL vial |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
Epoetin alfa 10000unt/mL solution |
Product containing precisely epoetin alfa 10000 unit/1 milliliter conventional release solution for injection (clinical drug) |
Epoetin alfa 20000unt/mL injection solution 1mL vial |
Epoetin alfa 20000 unit/mL solution for injection |
Epoetin alfa 2000unt/mL injection |
Epoetin alfa 2000 unit/mL solution for injection |
Epoetin alfa 2000unt/mL injection solution 1mL vial |
Epoetin alfa 2000 unit/mL solution for injection |
Epoetin alfa 2000unt/mL solution |
Epoetin alfa 2000 unit/mL solution for injection |
Epoetin alfa 3000unt/mL injection solution 1mL vial |
Product containing precisely epoetin alfa 3000 unit/1 milliliter conventional release solution for injection (clinical drug) |
Epoetin alfa 4000unt/mL injection solution 1mL vial |
Epoetin alfa 4000 unit/mL solution for injection |
Epoetin alfa 4000unt/mL solution |
Epoetin alfa 4000 unit/mL solution for injection |
Epoetin beta 10,000iu powder and solvent for injection solution cartridge |
Epoetin beta only product in parenteral dose form |
Epoetin beta 10,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
Epoetin beta 100,000iu powder and solvent for injection solution vial |
Epoetin beta only product in parenteral dose form |
Epoetin beta 100,000iu powder for conventional release solution for injection vial |
Epoetin beta only product in parenteral dose form |
Epoetin beta 20,000iu powder and solvent for injection solution cartridge |
Epoetin beta only product in parenteral dose form |
Epoetin beta 20,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
Epoetin beta 50,000iu powder and solvent for injection solution vial |
Epoetin beta only product in parenteral dose form |
Epoetin beta 50,000iu powder for conventional release solution for injection vial |
Epoetin beta only product in parenteral dose form |
Epoetin beta 500iu powder and solvent for injection solution vial |
Epoetin beta only product in parenteral dose form |
Epoetin beta 60,000iu powder and solvent for injection solution cartridge |
Epoetin beta only product in parenteral dose form |
Epoetin beta 60,000iu powder for conventional release solution for injection cartridge |
Epoetin beta only product in parenteral dose form |
Epoophoron |
Wolffian body rest |
Epstein syndrome |
MYH9-related disease (MYH9-RD) is an inherited giant platelet disorder with a complex phenotype characterized by congenital thrombocytopenia and possible subsequent manifestations of sensorineural hearing loss, presenile cataracts, elevation of liver enzymes, and/or progressive nephropathy often leading to end-stage renal disease (ESRD). Epstein syndrome, Fechtner syndrome, May-Hegglin anomaly and Sebastian syndrome, previously described as distinct disorders, represent some of the different clinical presentations of MYH9-RD. |
Eptifibatide 0.75mg injection |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Eptifibatide 0.75mg/mL injection |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Eptifibatide 0.75mg/mL injection solution 100mL bag |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Eptifibatide 750micrograms/mL infusion solution 100mL vial |
Product containing precisely eptifibatide 750 microgram/1 milliliter conventional release solution for injection (clinical drug) |
Equine anti-human thymocyte immunoglobulin 20mg/mL injection solution 5mL vial |
Product containing precisely equine antithymocyte immunoglobulin 20 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Equine arteritis virus antibody |
Viral antibody |
Equine infectious anemia virus antibody |
Viral antibody |
Equus asinus asinus |
Equus asinus |
Erect abdominal X-ray NOS |
Erect plain X-ray of abdomen (procedure) |
Erect abdominal X-ray NOS |
Erect plain X-ray of abdomen (procedure) |
Ergonovine maleate 200mcg/mL injection solution ampule |
Ergometrine 200 microgram/mL solution for injection |
Ergot compound allergy |
Allergy to ergot alkaloid (finding) |
Eribulin mesylate 0.5mg/mL conventional release solution for injection |
Product containing only eribulin in parenteral dose form (medicinal product form) |
Eribulin mesylate 0.5mg/mL solution for intravenous infusion |
Product containing only eribulin in parenteral dose form (medicinal product form) |
Erroneous concept |
Erroneous component (foundation metadata concept) |
Ertapenem 1g powder for infusion solution vial |
Ertapenem (as ertapenem sodium) 1 g powder for solution for injection vial |
Erwinia ananas |
Pantoea ananatis (organism) |
Erwinia cacticida |
Pectobacterium cacticida (organism) |
Erwinia cancerogena |
Enterobacter cancerogenus |
Erwinia carnegieana |
Genus Dickeya (organism) |
Erwinia carotovora |
Pectobacterium carotovorum (organism) |
Erwinia carotovora ss. atroseptica |
Pectobacterium atrosepticum (organism) |
Erwinia carotovora ss. betavasculorum |
Pectobacterium betavasculorum (organism) |
Erwinia carotovora ss. carotovora |
Pectobacterium carotovorum subspecies carotovorum (organism) |
Erwinia carotovora subsp odorifera |
Pectobacterium carotovorum subspecies odoriferum (organism) |
Erwinia cartovora subsp cartobora |
Pectobacterium carotovorum subspecies carotovorum (organism) |
Erwinia cartovora subsp wasabiae |
Pectobacterium wasabiae (organism) |
Erwinia chrysanthemi |
Dickeya chrysanthemi (organism) |
Erwinia cypripedii |
Pantoea cypripedii (organism) |
Erwinia herbicola |
Pantoea agglomerans |
Erwinia nigrifluens |
Brenneria nigrifluens (organism) |
Erwinia paradisiaca |
Dickeya paradisiaca (organism) |
Erwinia quercina |
Lonsdalea quercina (organism) |
Erwinia rhapontici |
Pectobacterium rhapontici (organism) |
Erwinia rubrifaciens |
Brenneria rubrifaciens (organism) |
Erwinia salicis |
Brenneria salicis (organism) |
Erwinia stewartii |
Pantoea stewartii subsp stewartii |
Erwinia uredovora |
Pantoea ananatis (organism) |
Erythema infectiosum virus |
Primate erythroparvovirus 1 (organism) |
Erythema multiforme due to mycoplasma infection |
Erythema multiforme due to Mycoplasma pneumoniae infection (disorder) |
Erythromycin 250mg e/c granules in capsule |
Product containing precisely erythromycin 250 milligram/1 each conventional release oral capsule (clinical drug) |
Erythromycin 250mg gastro-resistant oral capsule |
Product containing precisely erythromycin 250 milligram/1 each conventional release oral capsule (clinical drug) |
Erythromycin 250mg m/r capsule |
Product containing precisely erythromycin 250 milligram/1 each conventional release oral capsule (clinical drug) |
Erythromycin ethylsuccinate 100 mg/2.5mL |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 100mg/2.5mL oral suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 100mg/2.5mL suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 200mg/5mL |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 200mg/5mL liquid |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 200mg/5mL oral suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 200mg/5mL suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 40 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 400mg film |
Erythromycin (as erythromycin ethyl succinate) 400 mg oral tablet |
Erythromycin ethylsuccinate 400mg/5 mL |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 400mg/5mL oral suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 400mg/5mL powder |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin ethylsuccinate 400mg/5mL suspension |
Product containing precisely erythromycin (as erythromycin ethylsuccinate) 80 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Erythromycin lactobionate 1g injection (pdr for recon) |
Product containing only erythromycin in parenteral dose form (medicinal product form) |
Erythromycin lactobionate 1g powder for infusion solution vial |
Product containing only erythromycin in parenteral dose form (medicinal product form) |
Erythromycin lactobionate 500mg |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Erythromycin lactobionate 500mg injection (pdr for recon) |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Erythromycin lactobionate 500mg powder for infusion solution vial |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Erythromycin lactobionate 500mg/mL injection |
Product containing precisely erythromycin (as erythromycin lactobionate) 500 milligram/1 vial powder for conventional release solution for injection (clinical drug) |
Escherichia coli serotype O7:H157 |
Escherichia coli serotype O157:H7 (organism) |